These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213 [TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075 [TBL] [Abstract][Full Text] [Related]
24. The Epstein-Barr virus: a group 1 carcinogen? Niedobitek G Virchows Arch; 1999 Aug; 435(2):79-86. PubMed ID: 10599304 [TBL] [Abstract][Full Text] [Related]
25. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Khanna R; Moss DJ; Burrows SR Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141 [TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus as an agent of haematological disease. Tosato G; Taga K; Angiolillo AL; Sgadari C Baillieres Clin Haematol; 1995 Mar; 8(1):165-99. PubMed ID: 7663046 [TBL] [Abstract][Full Text] [Related]
27. Host genetics of Epstein-Barr virus infection, latency and disease. Houldcroft CJ; Kellam P Rev Med Virol; 2015 Mar; 25(2):71-84. PubMed ID: 25430668 [TBL] [Abstract][Full Text] [Related]
28. [Research progress on epstein-barr virus and its related lymphoma]. Wang TT; Yuan T; Zhang YZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1775-9. PubMed ID: 25543515 [TBL] [Abstract][Full Text] [Related]
29. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Sun Q; Burton R; Reddy V; Lucas KG Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048 [TBL] [Abstract][Full Text] [Related]
30. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211 [TBL] [Abstract][Full Text] [Related]
32. The human T cell immune response to Epstein-Barr virus. Landais E; Saulquin X; Houssaint E Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243 [TBL] [Abstract][Full Text] [Related]
33. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide. Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491 [TBL] [Abstract][Full Text] [Related]